Is Scienture Holdings going out of business?

Scienture Holdings, Inc. (SCNX) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Scienture Holdings, Inc. (SCNX) scores 15 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 234.48% (YoY)

Five questions, kept separate

Survival - Critical

3-6 mo of estimated runway from 2026-06-30, based on $8.2M of cash and short-term investments against $22.4M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

44.5% net-cash backing support a balanced pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 234.48% (YoY)
• Debt / Equity: -0.13x (Net Cash)
• ROIC: -72.68%
• Filing event risk: Going-Concern Warning (-8 pts)
• Revenue CAGR (3Y): -65.21%
• Return on Assets: -47.32%
• Revenue per Asset Efficiency: 460.92% QoQ (Strong monetization)
• Revenue growth YoY: 3249.96% (YoY) - Early-Stage Surge (low base)
• Price / Sales: 34.4x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)
• Operating leverage: -12848.6%
• Effective Tax Rate: 4.59% (loss-making)

Read from filings through 2026-08-20.

Price as of 2026-09-07.